Biotechnology

Humacyte

D. Boral Capital Reiterates Buy Rating on Humacyte Stock

Humacyte released FY2025 Q3 earnings on November 12 During-Market EST, actual revenue USD 753 K (forecast USD 922.83 K), actual EPS USD -0.1106 (forecast USD -0.1583)

Humacyte released FY2025 9 Months Earnings on November 12 During-Market EST, actual revenue USD 1.571 M, actual EPS USD -0.0591

Humacyte to Release FY2025 Q3 Earnings on November 12 During-Market (EST), Forecast Revenue USD 922.83 K, EPS USD -0.1583

Humacyte released FY2025 Q2 earnings on August 11 Pre-Market (EST), actual revenue USD 301K (forecast USD 1.004M), actual EPS USD -0.2422 (forecast USD -0.1616)

Humacyte released FY2025 Semi-Annual earnings on August 11 Pre-Market (EST), actual revenue USD 818K, actual EPS USD 0.0099

Humacyte to Release FY2025 Q2 Earnings on August 11 Pre-Market EST, Forecast Revenue USD 1.004 M, EPS USD -0.1616

Humacyte Inc. Annual Shareholders' Meeting Approves Director Elections and Increase in Authorized Common Stock

D. Boral Capital Reiterates Buy Rating on Humacyte

Humacyte's Novel Vascular Therapy Significantly Superior to Autologous AVF

Benchmark Downgrades HUMACYTE INC Target Price

Humacyte released FY2025 Q1 earnings on May 13 During-Market EST, actual revenue USD 517 K (forecast USD 764.83 K), actual EPS USD 0.2795 (forecast USD -0.19)

Humacyte Reports 2025 Q1 Earnings

Humacyte Inc reports quarterly earnings, loss of 19 cents per share

Humacyte to Release FY2025 Q1 Earnings on May 13 During-Market EST, Forecast Revenue USD 764.83K, EPS USD -0.19

Humacyte insider increased stock holdings, price rose

Chief Medical Officer Shamik Parikh Purchases Humacyte Stock

Humacyte released FY2024 Q4 earnings during market hours on March 28 (EST), with actual revenue of 0 USD (forecast 0 USD) and actual EPS of -0.1649 USD (forecast -0.25 USD)

Humacyte released FY2024 annual earnings during market hours on March 28 (EST), actual revenue 0 USD (forecast 214.29 K USD), actual EPS -1.255 USD (forecast -1.3485 USD)

Humacyte Q4 Financial Report: Operating Expenses of $28.088 Million, Net Income Improved to -$20.94 Million

Treasure Gbl

SMX Security Matters

Wheeler Real Estate

DigitalBridge

Irobot

Toro

Praxis Precision Medicines

Alumis

Top Kingwin

Lichen

Adma Biologics

Kiniksa Pharmaceuticals

Stoke Therapeutics

Rigel Pharma

OpGen

Vertex Pharma

Regeneron Pharma

Alnylam Pharma

Argenx

Beigene

Style Score

Growth Score

Revenue YoY

Net Profit YoY

Value Score

P/B Ratio

Dividend Ratio

Size Score

Market Cap Score

Market Cap

Revenue Score

Revenue

Multi Score

Profit Score

Profit Margin

Gross Margin

Total Assets YoY

Net Assets YoY

Cash Score

Cash Flow Margin

OCF YoY

Operating Score

Turnover

Debt Score

Gearing Ratio

Please note that a "Suspected value trap" is a stock that appears The stock looks financially sound and severely undervalued, but behind the low valuation is a long-term decline in business capacity or a serious financial crisis, or even the risk of bankruptcy in the short term.

Suspected value trap